Physician profile
Chaunce E Ruff
NPI 1225113186
$8,103.41
in general payments reported to CMS, 2019-2025
36 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,284 · 2022: $1,798 · 2023: $994 · 2024: $1,446 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,022.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,526.91 | 2021-2025 | Farxiga, Breztri |
| Abbvie INC. | $1,411.34 | 2021-2025 | |
| Glaxosmithkline, LLC. | $730.88 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $659.67 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.31 | 2021-2025 | Jardiance |
| Pfizer INC. | $452.46 | 2021-2025 | |
| Amgen INC. | $442.70 | 2021-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $437.74 | 2021-2025 | |
| Lilly USA, LLC | $185.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Mylan Specialty L.P. | $154.33 | 2021-2024 | Yupelri, Yupelri |
| Teva Pharmaceuticals USA, INC. | $148.00 | 2021-2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $143.51 | 2021-2024 | |
| Exact Sciences Corporation | $143.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $140.59 | 2021-2024 | Nexletol |
| Viiv Healthcare Company | $122.36 | 2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaunce Ruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.